{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:25:38Z","timestamp":1787772338123,"version":"build-2784847793"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,4]]},"abstract":"\n Background:<\/jats:title>\n Hydroxyurea (HU) is an hemoglobin F inducing agent used in the treatment of sickle cell disease (SCD).<\/jats:p>\n <\/jats:sec>\n \n Aim:<\/jats:title>\n The aim of this study is to determine the perception of HU by people living with SCD.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods:<\/jats:title>\n A pretested questionnaire was self-administered to known cases of SCD attending pediatrics and adult hematology clinics in three participating centers. Mothers of children <18 years responded on their behalf.<\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n There were 101 responders, 49 (48.5%) males and 52 (51.5%) females, of which 24 (23.8%) were children <18 years and 77 (76.2%) were adults. The majority (\n n<\/jats:italic>\n = 73, 72.3%) knew their phenotype. Up to 63 (62.4%) had crises in the past 3 months. Only 35 (34.7%) had heard of HU, many through their doctor (\n n<\/jats:italic>\n = 16, 45.7%), 8 (22.9%) through online resources, and 7 (20%) from friends. Only 12 (11.9%) had been exposed to HU therapy, of which 5 (41.7%) had discontinued therapy mostly due to side effects (\n n<\/jats:italic>\n = 2, 40%). The seven patients (58.3%) on continuous HU therapy for a duration of 6 months to over 5 years, all reported reduced hospital admissions and frequency of crises as benefits of the drug, whereas 4 (57.1%) had stopped requiring blood transfusion since starting therapy. Of those who had never taken HU, 53 (52.5%) believed that HU should be used in treating SCD and majority (\n n<\/jats:italic>\n = 32, 60.4%) would want to be commenced on the drug. However, 8 (15.1%) would decline therapy (mostly due to perceived associated side effects;\n n<\/jats:italic>\n = 4; 50%). Six (11.3%) were unsure if they would want the drug and 7 (13.2%) would have to discuss the decision first with their family. There were 8 (8.9%) responders who did not think HU will be beneficial in SCD and would decline treatment, while 26 (29.2%) were unsure of both the benefits of the drug or of commencing therapy.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion:<\/jats:title>\n The findings from this study suggest that HU is beneficial for patients with SCD; however, the awareness of this medication among SCD patients is still low in our environment. Some SCD patients would decline the use of HU due to perceived side effects. We recommend that more awareness on HU be created and coordinated multi-center studies on the efficacy of HU in the Nigerian population be carried out.<\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/aam.aam_36_20","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T12:48:06Z","timestamp":1716382086000},"page":"127-131","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Perception to Hydroxyurea Therapy in Patients with Sickle Cell Disease"],"prefix":"10.4103","volume":"20","author":[{"given":"Kaladada I.","family":"Korubo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nkemsinachi Maryanne","family":"Onodingene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen Chioma","family":"Okoye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah E.","family":"Omunakwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-10-20240831","doi-asserted-by":"crossref","first-page":"49","DOI":"10.4103\/archms.archms_21_18","article-title":"Quality of life assessment among individuals with sickle cell disease attending haematology clinic of a tertiary hospital in Northwest Nigeria","volume":"3","author":"Babale","year":"2018","journal-title":"Arch Med Surg"},{"key":"R3-10-20240831","doi-asserted-by":"crossref","first-page":"80","DOI":"10.4103\/2384-5589.197965","article-title":"Health-related quality of life in sickle cell disease subjects in Benin City, Nigeria","volume":"15","author":"Nwogoh","year":"2016","journal-title":"Afr J Med Health Sci"},{"key":"R4-10-20240831","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1517\/14740338.2015.1088827","article-title":"Hydroxyurea therapy for sickle cell anemia","volume":"14","author":"McGann","year":"2015","journal-title":"Expert Opin Drug Saf"},{"key":"R5-10-20240831","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1046\/j.1365-2141.2003.03849.x","article-title":"The role of hydroxyurea in sickle cell disease","volume":"120","author":"Harsey","year":"2003","journal-title":"Br J Haematol"},{"key":"R6-10-20240831","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12288-013-0261-4","article-title":"Hydroxyurea in sickle cell disease: Drug review","volume":"30","author":"Agrawal","year":"2014","journal-title":"Indian J Hematol Blood Transfus"},{"key":"R7-10-20240831","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/bjh.15235","article-title":"Guidelines for the use of hydroxycarbamide in children and adults with sickle cell disease","volume":"181","author":"Qureshi","year":"2018","journal-title":"Br J Haematol"},{"key":"R8-10-20240831","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1097\/MOH.0b013e32834521dd","article-title":"Hydroxyurea for sickle cell anemia: What have we learned and what questions still remain?","volume":"18","author":"McGann","year":"2011","journal-title":"Curr Opin Hematol"},{"key":"R9-10-20240831","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4314\/ahs.v17i1.31","article-title":"Hydroxyurea therapy in adult Nigerian sickle cell disease: A monocentric survey on pattern of use, clinical effects and patient's compliance","volume":"17","author":"Adewoyin","year":"2017","journal-title":"Afr Health Sci"},{"key":"R10-10-20240831","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4103\/atp.atp_31_17","article-title":"Hydroxyurea: Modifier of pathophysiology in sickle cell anemia","volume":"9","author":"Akinsegun","year":"2018","journal-title":"Ann Trop Pathol"},{"key":"R11-10-20240831","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4103\/smj.smj_29_18","article-title":"The use of hydroxycarbamide in children with sickle cell anemia","volume":"21","author":"Rufai","year":"2018","journal-title":"Sahel Med J"},{"key":"R12-10-20240831","doi-asserted-by":"crossref","first-page":"167","DOI":"10.4103\/nmj.NMJ_111_18","article-title":"An assessment of knowledge, awareness, and attitude of undergraduates toward sickle cell disease in Lagos, Nigeria","volume":"58","author":"Uche","year":"2017","journal-title":"Niger Med J"},{"key":"R13-10-20240831","doi-asserted-by":"crossref","first-page":"5300","DOI":"10.1182\/blood-2009-04-146852","article-title":"How I use hydroxyurea to treat young patients with sickle cell anemia","volume":"115","author":"Ware","year":"2010","journal-title":"Blood"},{"key":"R14-10-20240831","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1182\/blood-2019-128185","article-title":"Level of utilization and provider-related barriers to hydroxyurea use in the treatment of sickle cell disease in Jos, Nigeria","volume":"134","author":"Ofakunrin","year":"2019","journal-title":"Blood"},{"key":"R15-10-20240831","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1001\/jama.289.13.1645","article-title":"Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: Risks and benefits up to 9 years of treatment","volume":"289","author":"Steinberg","year":"2003","journal-title":"JAMA"},{"key":"R16-10-20240831","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/jpepsy\/jsv084","article-title":"Systematic and meta-analytic review: Medication adherence among pediatric patients with sickle cell disease","volume":"41","author":"Loiselle","year":"2016","journal-title":"J Pediatr Psychol"},{"key":"R17-10-20240831","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.hemonc.2018.01.001","article-title":"Beliefs about hydroxyurea in youth with sickle cell disease","volume":"11","author":"Badawy","year":"2018","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"R18-10-20240831","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1186\/s12955-017-0713-x","article-title":"Adherence to hydroxyurea, health-related quality of life domains, and patients\u2019 perceptions of sickle cell disease and hydroxyurea: A cross-sectional study in adolescents and young adults","volume":"15","author":"Badawy","year":"2017","journal-title":"Health Qual Life Outcomes"},{"key":"R19-10-20240831","doi-asserted-by":"crossref","first-page":"3658","DOI":"10.1182\/blood-2018-99-112586","article-title":"Safety and efficacy of dose-escalation hydroxyurea therapy in infants and young children: A retrospective cohort study","volume":"132","author":"George","year":"2018","journal-title":"Blood"},{"key":"R20-10-20240831","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1182\/blood.V114.22.242.242","article-title":"Hydroxyurea in children with sickle cell disease: Practice patterns and barriers to utilization","volume":"114","author":"Brandow","year":"2009","journal-title":"Blood"}],"updated-by":[{"DOI":"10.4103\/1596-3519.326202","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2021,7,1]],"date-time":"2021-07-01T00:00:00Z","timestamp":1625097600000}}],"container-title":["Annals of African Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_36_20","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:39:32Z","timestamp":1787769572000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/aam.aam_36_20"}},"subtitle":["Report from 3 Centers"],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/aam.aam_36_20","relation":{},"ISSN":["1596-3519"],"issn-type":[{"value":"1596-3519","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]}}}